search
BioPharma Dive
Trends
- 1Shionogi to pay $2 billion for rare disease startup▼Shionogi pays $2B to acquire a rare disease startup
Japanese drugmaker Shionogi has agreed to acquire a rare disease-focused biotech startup in a deal worth roughly $2 billion. The acquisition, reported by BioPharma Dive, signals Shionogi's push to expand beyond its core infectious disease business into rare and specialty medicines, as larger pharma companies continue buying up innovative biotech pipelines.
- 2AI reshapes the biopharma factories of tomorrow●How AI is transforming biopharma manufacturing facilities of the future
Biopharma Dive reports that artificial intelligence is changing how drug manufacturing facilities are designed and operated. AI tools are being used to plan smarter factories, improve process control and boost efficiency in producing biologics and other medicines. The report points to a shift in how the pharmaceutical industry thinks about building the production plants of the future.